Jazz Pharma confirms FY2024 revenue guidance met at J.P. Morgan conference

Jazz Pharmaceuticals plc

Company expects to meet previously announced total, neuroscience and oncology revenue guidance for year ended Dec 31, 2024.
Outlook disclosed at J.P. Morgan Healthcare Conference on Jan 14, 2025.
No specific revenue or EPS figures provided; guidance ranges unchanged.

item 2.02 item 9.01

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001193125-25-004989

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.